The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients

AYŞE KARATAŞ
ÜMİT YAVUZ MALKAN
MUSTAFA VELET
HALUK DEMİROĞLU
YAHYA BÜYÜKAŞIK

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical

Part of the Medical Sciences Commons

Recommended Citation
KARATAŞ, AYŞE; MALKAN, ÜMİT YAVUZ; VELET, MUSTAFA; DEMİROĞLU, HALUK; BÜYÜKAŞIK, YAHYA; DİZMAN, GÜLCİN TELLİ; İNKAYA, AHMET ÇAĞKAN; ERDOĞDU, BATUHAN; ÇINAR, OLGU ERKİN; KARAKULAK, ELİFÇAN ALADAĞ; AKSU, SALİH; HAZNEDAROĞLU, İBRAHİM CELALETİN; ÖZCEBE, OSMAN İLHAMİ; SAYINALP, NİLGÜN; and GÖKER, HAKAN (2021) "The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients," Turkish Journal of Medical Sciences: Vol. 51: No. 4, Article 6. https://doi.org/10.3906/sag-2103-72
Available at: https://journals.tubitak.gov.tr/medical/vol51/iss4/6

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.
The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients

Authors
AYŞE KARATAŞ, ÜMİT YAVUZ MALKAN, MUSTAFA VELET, HALUK DEMİROĞLU, YAHYA BÜYÜKAŞIK, GÜLCİN TELLİ DİZMAN, AHMET ÇAĞKAN İNKAYA, BATUHAN ERDOĞDU, OLGU ERKİN ÇINAR, ELİFCAN ALADAĞ KARAKULAK, SALİH AKSU, İBRAHİM CELALETTİN HAZNEDAROĞLU, OSMAN İLHAMİ ÖZCEBE, NİLGÜN SAYINALP, and HAKAN GÖKER

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol51/iss4/6
The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients

Ayşe KARATAŞ1, Ümit Yavuz MALKAN1, Mustafa VELET1, Haluk DEMİROĞLU1, Yahya BÜYÜKASIK1, Gülçin TELLİ DİZMAN2, Ahmet Çağkan İNKAYA2, Batuhan ERDOĞDU2, Olgu Erkin ÇINAR3, Elifcan ALADAĞ4, Salih AKSU1, İbrahim Celalettin HAZNEDAROĞLU1, Osman ÖZCEBE4, Nilgün SAYINALP4, Hakan GÖKER4

1Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey
2Department of Infectious Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey
3Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
4Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey

Background/aim: The disease caused by SARS-CoV-2 was named as COVID-19. There is as yet insufficient information about the effects of HSCT on the clinical course of COVID-19. In the present study, we aimed to investigate the clinical course of COVID-19 in patients who had undergone HSCT.

Materials and methods: We analyzed baseline characteristics, clinical course and findings of COVID-19, hospitalization and death rates, overall survival, and case fatality rates of HSCT recipients diagnosed with COVID-19 retrospectively.

Results: 57.6% of the patients underwent AHSCT, and 42.4% underwent allo-HSCT. 60.6%, 27.3%, and 12.1% of the patients had mild, moderate, and severe COVID-19 or critical illness, respectively. Overall, 45.5% were hospitalized, 12.1% required intensive care, and 9.1% necessitated invasive mechanical ventilation. The total CFR was 9.1% in HSCT recipients, 22.2% in patients with active hematologic malignancy, and 4.2% in patients without active hematologic malignancy.

Conclusion: It can be concluded that mortality of HSCT recipients is lower in patients whose primary disease is in remission compared to those that are not in remission. Further studies with larger group patients are needed in order to delineate the effects of COVID-19 on HSCT patients.

Key words: Hematopoietic stem cell transplantation, bone marrow transplant, COVID-19

1. Introduction

The disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first discovered in Wuhan, China and named as coronavirus disease 2019 (COVID-19) then spread all over the world, and declared as a pandemic by the World Health Organization [1].

Clinical course of the disease varies from asymptomatic disease to significant morbidity and mortality due to respiratory failure. Advanced age, male sex, hypertension, diabetes mellitus, cardiovascular diseases, and cancer have been shown as risk factors worsening outcomes. There are studies that show higher mortality rates in hematologic cancer patients [2,3]. The characteristics of the disease course in immunosuppressive patients are not exactly known yet [4]. Hematopoietic stem cell transplantation (HSCT) recipients are considered to be at risk due to severe immunosuppressive therapy and immune system dysregulation after HSCT [5]. There is as yet insufficient information about the effects of COVID-19 on the clinical course of HSCT patients. In the present study, we aimed to investigate the effects of COVID-19 in patients who had undergone HSCT.

2. Materials and methods

According to the hospital medical records, 33 patients followed in the stem cell transplantation unit of Hacettepe University Hematology Department were diagnosed with COVID-19 between 11th March and 30th November 2020. The data of these patients was analyzed retrospectively. COVID-19 was diagnosed with positive result of reverse-
transcriptase polymerase chain reaction (RT-PCR) test from upper respiratory samples or bronchoalveolar lavage fluid. The disease with only mild symptoms (cough, fever, anosmia, fatigue) was evaluated as mild disease. The disease with clinical or radiological findings of pneumonia, but not requiring supportive oxygen therapy was evaluated as moderate disease. Patients with pneumonia and oxygen saturation below 93% or respiratory rate above 30/min were considered to have severe COVID-19. The condition of the patients with respiratory failure, shock or multi-organ failure was evaluated as critical illness [6]. Some high-risk patients with mild COVID-19 were hospitalized for observation purposes only.

The approvals were obtained from the Turkish Ministry of Health and the local ethics committee with decision number 2020/20-54.

IBM SPSS Statistics for Windows v: 25.0 (IBM Corp., Armonk, NY, USA) was used for statistical analyses. Categorical data was analyzed using Chi-square or Fisher's exact test. The distribution of continuous data was examined. Mean ± standard deviation and median (minimum-maximum) values were given for normally distributed continuous and nonnormally distributed variables, respectively. At the time of last follow-up, patients who were alive were censored for overall survival analysis. The Kaplan–Meier method was used for overall survival analysis.

3. Results

Thirty-three patients were included in the study. Median age was 57 (27–71) years. Nineteen (57.6%) of the patients underwent autologous hematopoietic stem cell transplantation (AHSCT), and 14 (42.4%) underwent allogeneic hematopoietic stem cell transplantation (Allo-HSCT). Nine (27.3%) had uncontrolled primary disease, and 4 (12.1%) were on calcineurin inhibitors at the time of COVID-19 diagnosis. Twelve (85.7%) of allo-HSCT recipients were transplanted from 10/10 human leukocyte antigen (HLA) matched related donors, two of them (14.3%) from haploidentical donors. The patients baseline characteristics are outlined in Table 1.

Among the patients, 23 (69.7%) of them developed fever in the course of COVID-19. Twenty (60.6%), 9 (27.3%), and 4 (12.1%) of the patients had mild, moderate and severe COVID-19 or critical illness, respectively. Fifteen (45.5%) were hospitalized, 4 (12.1%) required intensive care, and 3 patients (9.1%) needed invasive mechanical ventilation. A patient, who refused hospitalization died at home. Favipiravir, which is a ribonucleic acid polymerase inhibitor, was the most common antiviral medication used by the patients. Detailed COVID-19 outcomes of the patients are given in Table 2.

| Median Age (min-max) | 57 (27-71) years |
|----------------------|------------------|
| Gender, n (%)        |                  |
| Male                 | 21 (63.6%)       |
| Female               | 12 (36.4%)       |
| Time from HSCT to COVID-19 Median (min-max) | 868 (31-2368) days |
| Primary Disease (Requiring HSCT), n (%) |                  |
| MM                   | 9 (27.3%)        |
| HL                   | 1 (3.0%)         |
| NHL                  | 8 (24.2%)        |
| AML                  | 5 (15.2%)        |
| ALL                  | 3 (9.1%)         |
| PID                  | 2 (6.1%)         |
| MF                   | 1 (3.0%)         |
| MDS                  | 3 (9.1%)         |
| ITP                  | 1 (3.0%)         |
| HSCT, n (%)          |                  |
| AHSCT                | 19 (57.6%)       |
| Allo-HSCT            | 14 (42.4%)       |
| Uncontrolled Primary Disease, n (%) | 9 (27.3%) |
| Use of Immunosuppressive Drugs, n (%) |                  |
| (Calcineurin inhibitors) | 4 (12.1%)       |
| Donor (n=14)         |                  |
| Full matched donor, n (%) | 12 (83.3%) |
| Haploidentical, n (%) | 2 (16.7%)       |
| GVHD, n (%)          | 6 (18.2%)        |
| Chronic Diseases, n (%) |               |
| CAD                  | 4 (12.1 %)       |
| CKD                  | 7 (21.2%)        |
| HT                   | 8 (24.2 %)       |
| COPD                 | 1 (3.0 %)        |
| DM                   | 3 (9.1 %)        |
| Non-hematologic malignancy | 2 (6.1 %)       |

*MM: multiple myeloma, HL: hodgkin-lymphoma: NHL: nonhodgkin lymphoma, AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, PID: primary immunodeficiency, MF: mycosis fungoides, MDS: myelodysplastic syndrome, ITP: immune thrombocytopenia, GVHD: graft versus host disease, CAD: coronary artery disease, CKD: chronic kidney disease, HT: hypertension, COPD: chronic obstructive pulmonary disease, DM: diabetes mellitus.

A total of 6 patients had concomitant graft versus host disease (GVHD) (acute gastrointestinal and cutaneous: two patients, chronic cutaneous and gastrointestinal: two
patients, chronic cutaneous: two patients) at the time of COVID-19 diagnosis. The course of the GVHD did not get worse in these patients.

Among the hospitalized patients, 13 (86.7%) of them were male, and the remaining 2 (13.3%) were female. The difference was statistically significant (p < 0.05). Hospital admission rates according to sex, HSCT type, remission status, and presence of GVHD are given in Table 3.

Median follow-up time was 28 days (2–262 days). During this time, 3 of 33 patients (9.1%) died. The case fatality rate was 9.1% in all HSCT recipients, 22.2% in patients with active hematologic malignancy, 4.2% in patients without active hematologic malignancy, and 25.0% in who was on immunosuppressive drugs. The mortality rates according to sex, HSCT type, remission status, presence of GVHD, and use of immunosuppressive drugs are given in Table 4.

The mortality and hospitalization rates were calculated separately for the treatments. The detailed data on COVID-19 treatments received by the patients are given in Table 5. The treatment records of a patient who refused hospitalization and treated at home were not available. In univariate survival analysis, there was not statistically significant difference between the AHSCT and allo-HSCT recipients (p = 0.39). Kaplan–Meier survival curve of AHSCT and allo-HSCT recipients is shown in Figure.

### 4. Discussion

Information on the course of COVID-19 in HSCT recipients remained scarce, and mostly derived from case series involving limited number of patients. Survival rate of the HSCT recipients is a matter of debate. Sultan et al. and Haroon et al. did not report any mortality among 7 and 11 HSCT recipients, respectively [3,5]. However, Varma et al. published the outcomes of HSCT recipients with COVID-19 where 32% of the patients were treated in the intensive care unit and 21% died [7]. In another case series, 2 of 7 HSCT recipients died due to COVID-19 [8].

### Table 2. The clinical findings in HSCT patients.

| Symptoms                  | n (%)  |
|---------------------------|--------|
| Fever                     | 23 (69.7%) |
| Cough                     | 14 (42.4%) |
| Myalgia                   | 18 (54.6%) |
| Headache                  | 19 (57.6%) |
| Anosmia                   | 14 (42.4%) |
| Diarrhea                  | 5 (15.2%)  |
| Sore throat               | 4 (12.1%)  |
| Shortness of Breath       | 10 (30.3%) |
| COVID-19 Severity         |        |
| Mild                      | 20 (60.6 %) |
| Moderate                  | 9 (27.3 %) |
| Severe or Critical Disease| 4 (12.1 %) |

| Hospitalization           | n (%)  |
|---------------------------|--------|
| n (%)                     | 15 (45.5%) |
| Days, median (min-max)    | 12 (1-57) days |

| Treatment for COVID-19 (n, %) |        |
|------------------------------|--------|
| Hydroxychloroquine + Favipiravir | 5 (15.6%) |
| Favipiravir                   | 24 (75%) |
| Azithromycin + Hydroxychloroquine | 3 (9.4%) |

| Intensive Care Unit Admission |        |
|------------------------------|--------|
| n (%)                        | 4 (12.1%) |
| Days (mean ± SD)             | 15.2 ± 12.7 |
| Mechanical Ventilation, n (%)| 3 (9.1%) |
| Case Fatality Rate           | 3/33 (9.1%) |
| Duration to Death from COVID-19 (days) (mean ± SD) | 14.6 ± 6.8 |
In another study conducted in Spain, mortality was 20% in allo-HSCT recipients, and 24% in AHSCT recipients [9]. In another study, the CFR was 15.6% in HSCT recipients. The CFR of the HSCT recipients who were receiving immunosuppressive treatment was reported as 33% in that study [10]. The patients on immunosuppressive treatment can be considered at high risk for COVID-19 as well as other viral infections. In a cohort study examining the results of 318 HSCT recipients, overall survival 30 days after the COVID-19 diagnosis was 68% (95% CI 58–77) in allo-HSCT recipients and 67% (95% CI 55–78) in AHSCT recipients [11]. In the present study, case fatality rate (CFR) is 9.1% (3/33) in all HSCT recipients, 22.2% (2/9) in patients with active hematologic malignancy, and 4.2% (1/24) in patients without active hematologic malignancy. All of the patients received favipiravir as soon as the diagnosis was made which could lead to favorable outcome in the present study [12,13]. This study reflects our experience though with a limited number of HSCT recipients, given insight in the outcome of HSCT patients.

Table 3. Hospitalization rates according to parameters.

| Patients (n = 33) | Hospitalized | Non-Hospitalized | P-value |
|------------------|--------------|------------------|---------|
| Gender           |              |                  |         |
| Female (n = 12)  | 2 (13.3%)    | 10 (55.6%)       | 0.01    |
| Male (n = 21)    | 13 (86.7%)   | 8 (44.4%)        |         |
| HSCT             |              |                  | 0.65    |
| AHSCCT           | 8 (53.3%)    | 11 (61.1%)       |         |
| Allo-HSCT        | 7 (46.7%)    | 7 (38.9%)        |         |
| Remission Status of Primary Disease |              |                  | 0.47    |
| Yes              | 7 (46.7%)    | 2 (11.1%)        |         |
| No               | 8 (53.3%)    | 16 (88.9%)       |         |
| GVHD (in Allo-HSCT patients, n = 14) |              |                  | 0.59    |
| Yes (n = 6)      | 2 (28.6%)    | 4 (57.1%)        |         |
| No (n = 8)       | 5 (71.4%)    | 3 (42.9%)        |         |

Table 4. The mortality rates according to parameters.

| Patients (n = 33) | Death (n = 3) | Survivor (n = 30) | P-value |
|------------------|--------------|-------------------|---------|
| Gender           |              |                   |         |
| Male             | 3 (100.0%)   | 18 (60.0%)        | 0.2     |
| Female           | 0 (0.0%)     | 12 (40.0%)        |         |
| HSCT             |              |                   | 0.56    |
| AHSCCT           | 1 (33.3%)    | 18 (60.0%)        |         |
| Allo-HSCT        | 2 (66.7%)    | 12 (40.0%)        |         |
| Remission Status of Primary Disease |              |                   | 0.174   |
| Yes (n = 9)      | 2 (66.7%)    | 7 (23.3%)         |         |
| No (n = 24)      | 1 (33.3%)    | 23 (76.7%)        |         |
| Use of Immunosuppressive Drug |              |                   | 0.33    |
| Yes (n = 4)      | 1 (33.3%)    | 3 (10.0%)         |         |
| No (n = 29)      | 2 (66.7%)    | 27 (90.0%)        |         |
| GVHD (n=14)      |              |                   | 1.0     |
| Yes (n = 6)      | 1 (50.0%)    | 5 (41.7%)         |         |
| No (n = 8)       | 1 (50.0%)    | 7 (58.3%)         |         |
with COVID-19 infection. CFR was 9.1% in all patients, and 4.2% in patients with primary disease in remission. Based on the data above presented, it can be concluded that mortality of HSCT recipients is lower in patients whose primary disease is in remission compared to ones that are not in remission. Further studies with large group patients are needed in order to delineate the effects of COVID-19 in HSCT patients.

Conflict of interest
The authors declare they have no conflicts of interest.

Table 5. Death and hospitalization rates according to COVID-19 treatment*.

|                     | Hydroxychloroquine + Favipiravir n = 5 | Azithromycin + Hydroxychloroquine n = 3 | Favipiravir n = 24 |
|---------------------|----------------------------------------|----------------------------------------|--------------------|
| Hospitalization     | 4 (80.0%)                              | 1 (33.3%)                              | 13 (54.2%)         |
| Non-Hospitalized    | 1 (20.0%)                              | 2 (66.7%)                              | 11 (45.8%)         |
| Dead                | 0 (0.0%)                               | 0 (0.0%)                               | 3 (12.5%)          |
| Survivor            | 5 (100.0%)                             | 3 (100.0%)                             | 21 (87.5%)         |

*For this table n = 32, since the treatment records of a patient were not available.

Informed consent
As the standard action of Hacettepe University Faculty of Medicine hospitals, it was confirmed from the patient records that all patients included in the study gave informed consent for the standard diagnosis and treatment procedures at the time of admission to the hospital. The approvals were obtained from the Turkish Ministry of Health and the local ethics committee with decision number 2020/20-54.

References
1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ et al. Clinical characteristics of Coronavirus disease 2019 in China. New England Journal of Medicine 2020; 382 (18): 1708-1720. doi: 10.1056/NEJMoa2002032
2. Shah V, Ko Ko T, Zuckerman M, Vidler J, Sharif S et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. British Journal of Haematology 2020; 190 (5): e279-e282. doi: 10.1111/bjh.16935
3. Haroon A, Alnassani M, Aljurf M, Ahmed SO, Shaheen M et al. COVID-19 post hematopoietic cell transplant, a report of 11 cases from a single center. Mediterranean Journal of Hematology and Infectious Diseases 2020; 12 (1): e2020070. doi: 10.4084/mjhid.2020.070

4. Ljungman P, Mikuliska M, De la Camara R, Basak GW, Chabannon C et al. The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplantation 2020; 55 (11): 2071-2076. doi: 10.1038/s41409-020-0919-0

5. Sultan AM, Mahmoud HK, Fathy GM, Abdelfattah NM. The outcome of hematopoietic stem cell transplantation patients with COVID-19 infection. Bone Marrow Transplantation 2021; 56: 971-973. doi: 10.1038/s41409-020-01094-9

6. Çalış Başaran N, Uyaroğlu OA, Telli Dizman G, Özşık L, Şahin TK et al. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. Turkish Journal of Medical Sciences 2020; 51: 411-420. doi: 10.3906/sag-2006-173

7. Varma A, Kosuri S, Ustun C, Ibrahim U, Moreira J et al. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter. Leukemia 2020; 34 (10): 2809-2812. doi: 10.1038/s41375-020-01019-x

8. Kanellopoulos A, Ahmed MZ, Kishore B, Lovell R, Horgan C et al. COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience. British Journal of Haematology 2020; 190 (2): e67-e70. doi: 10.1111/bjh.16856

9. Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, Martínez-Fernández JR, Crespo M et al. COVID-19 in transplant recipients: the Spanish experience. American Journal of Transplantation 2021; 21 (5): 1825-1837. doi: 10.1111/ajt.16369

10. Altuntas F, Ata N, Yigenoglu TN, Basçı S, Dal MS et al. COVID-19 in hematopoietic cell transplant recipients. Bone Marrow Transplantation 2021; 56 (4): 952-955. doi: 10.1038/s41409-020-01084-x

11. Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. The Lancet Haematology 2021; 8 (3): e185-e193. doi: 10.1016/s2352-3026(20)30429-4

12. Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. Journal of Virology 2013; 87 (7): 3741-3751. doi: 10.1128/jvi.02346-12

13. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proceedings of the National Academy of Sciences 2010; 107 (2): 882-887. doi: 10.1073/pnas.0909603107